Terumo Neuro agrees to acquire Arsenal Medical, adding NeoCast embolic technology
AI Summary- Terumo Neuro signed an agreement to acquire Arsenal Medical and its NeoCast technology.
- 96% of EMBO-02 subjects achieved at least 50% hematoma-volume reduction.
- RADIANT received FDA IDE approval, and its first patients have been enrolled.